Meeting
2016 ASCO Annual Meeting
CHK1 inhibition as a therapeutic approach in KRAS mutated and squamous cell carcinoma NSCLC patients.
Authors
Daniela Morales-Espinosa
Instituto Oncologico Dr Rosell, Translational Research laboratory. Quiron-Dexeus University Hospital, Barcelona, Spain
Daniela Morales-Espinosa , Silvia García-Román , Miguel Angel Molina-Vila , Ana Gimenez Capitan , Jordi Bertran-Alamillo , Pedro Mendez , Santiago Viteri Ramirez , Niki Karachaliou , Rafael Rosell
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
New Targets and New Technologies
Citation
J Clin Oncol 34, 2016 (suppl; abstr 11581)
DOI
10.1200/JCO.2016.34.15_suppl.11581
Abstract #
11581
Poster Bd #
278
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Circulating tumor DNA–based genomic landscape of KRAS wild-type pancreatic adenocarcinoma.
First Author: Brendon Fusco
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Molecular genetic sequencing of neuroendocrine tumors of the gastrointestinal tract.
First Author: Alexandra Androsova
Poster
2018 ASCO Annual Meeting
Exploring the association between somatic molecular features and tumor mutation burden in 513 non–small-cell lung cancer.
First Author: Chenchen Zhu
Poster
2020 Gastrointestinal Cancers Symposium
Phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response (DDR) pathway deficient neoplasms including cholangiocarcinoma.
First Author: Thomas J. George